文献速递神经肿瘤

青少年和青年高级别胶质瘤的组织分子特征与成人及儿童患者不同

High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts.
PubMed 文献 · Neuro Oncol · 2020-01-01

该多中心回顾性研究分析了1998至2013年法国法兰西岛地区成人与儿童神经外科单位的112例15至25岁高级别胶质瘤患者,基于80例有完整资料者进行整合诊断。结果显示青少年和青年高级别胶质瘤以儿童亚型(组蛋白H3突变型40%)为主,兼具成人亚型(IDH突变型28%),H3G34突变型(14%)为该人群最特异亚组;WHO分级无预后价值,而分子亚组分型具有重要预后意义。

要点

  • 青少年和青年高级别胶质瘤中儿童亚型(H3突变型)占40%,成人亚型(IDH突变型)占28%。
  • H3G34突变型(14%)是青少年和青年高级别胶质瘤最特异的亚组。
  • WHO分级无预后价值,分子亚组分型具有重要预后意义。

核心结论

  • 青少年和青年高级别胶质瘤可能受益于由分子亚型而非年龄组驱动的特定分类。
  • 需要儿童与成人神经肿瘤团队协作以改善青少年和青年高级别胶质瘤的管理。

研究设计与样本

  • 多中心回顾性研究,纳入1998至2013年法国法兰西岛地区成人与儿童神经外科单位的112例青少年和青年患者。
  • 纳入标准为年龄15至25岁、组织病理学诊断为高级别胶质瘤、有可用临床数据及术前和随访MRI。
  • 对MRI和肿瘤样本进行中心审阅,并行免疫组化及靶向/二代测序、全外显子组测序和DNA甲基化分析,按2016年WHO分类进行整合诊断。
  • 基于80例有完整记录的青少年和青年患者进行分析。

主要发现

  • 基于80例有完整记录的患者,高级别胶质瘤构成异质的临床病理和分子组,儿童亚型(组蛋白H3突变型)占40%,成人亚型(IDH突变型)占28%。
  • 少突胶质细胞瘤、IDH突变型和1p/19q共缺失罕见,而「罕见成人IDH突变」频率相对较高(20%)。
  • H3G34突变型(14%)是青少年和青年中最特异的亚组。
  • 在H3K27突变亚组中,非脑干弥漫性中线胶质瘤(66.7%)比弥漫性内生性脑桥胶质瘤(23.8%)更常见,与儿童中所观察到的相反。
  • WHO分级无预后价值,但分子亚组分型具有重要预后意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Considering that pediatric high-grade gliomas (HGGs) are biologically distinct from their adult counterparts, the objective of this study was to define the landscape of HGGs in adolescents and young adults (AYAs). METHODS: We performed a multicentric retrospective study of 112 AYAs from adult and pediatric Ile-de-France neurosurgical units, treated between 1998 and 2013 to analyze their clinicoradiological and histomolecular profiles. The inclusion criteria were age between 15 and 25 years, histopathological HGG diagnosis, available clinical data, and preoperative and follow-up MRI. MRI and tumoral samples were centrally reviewed. Immunohistochemistry and complementary molecular techniques such as targeted/next-generation sequencing, whole exome sequencing, and DNA-methylation analyses were performed to achieve an integrated diagnosis according to the 2016 World Health Organization (WHO) classification. RESULTS: Based on 80 documented AYA patients, HGGs constitute heterogeneous clinicopathological and molecular groups, with a predominant representation of pediatric subtypes (histone H3-mutants, 40%) but also adult subtypes (isocitrate dehydrogenase [IDH] mutants, 28%) characterized by the rarity of oligodendrogliomas, IDH mutants, and 1p/19q codeletion and the relative high frequency of "rare adult IDH mutations" (20%). H3G34-mutants (14%) represent the most specific subgroup in AYAs. In the H3K27-mutant subgroup, non-brainstem diffuse midline gliomas are more frequent (66.7%) than diffuse intrinsic pontine gliomas (23.8%), contrary to what is observed in children. We found that WHO grade has no prognostic value, but molecular subgrouping has major prognostic importance. CONCLUSIONS: HGGs in AYAs could benefit from a specific classification, driven by molecular subtyping rather than age group. Collaborative efforts are needed from pediatric and adult neuro-oncology teams to improve the management of HGGs in AYAs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Roux A, Pallud J, Saffroy R, et al. High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts. Neuro Oncol. 2020. PMID: 32025728. doi:10.1093/neuonc/noaa024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。